Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

34.09
Delayed Data
As of May 27
 +0.66 / +1.97%
Today’s Change
30.30
Today|||52-Week Range
46.24
-21.01%
Year-to-Date
Bull Vs. Bear: Myriad Genetics, Inc.
May 25 / MotleyFool.com - Paid Partner Content
Myriad Genetics Brings myVectra Web Portal for RA Patients
May 17 / Zacks.com - Paid Partner Content
Better Buy: Myriad Genetics, Inc. vs. Exact Sciences
May 17 / MotleyFool.com - Paid Partner Content
Myriad Genetics: Test Revenues Strong, Currency Woes Stay
May 16 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close33.43
Today’s open33.50
Day’s range33.45 - 34.45
Volume855,284
Average volume (3 months)959,108
Market cap$2.4B
Dividend yield--
Data as of 4:00pm ET, 05/27/2016

Growth & Valuation

Earnings growth (last year)-52.00%
Earnings growth (this year)+13.47%
Earnings growth (next 5 years)+14.05%
Revenue growth (last year)-7.08%
P/E ratio23.0
Price/Sales3.50
Price/Book3.55

Competitors

 Today’s
change
Today’s
% change
IPXLImpax Laboratories I...+0.55+1.67%
GLPGGalapagos NV+0.92+1.60%
LGNDLigand Pharmaceutica...+0.85+0.70%
MDCOMedicines Co+0.45+1.21%
Data as of 4:00pm ET, 05/27/2016

Financials

Next reporting dateAugust 9, 2016
EPS forecast (this quarter)$0.38
Annual revenue (last year)$723.1M
Annual profit (last year)$80.2M
Net profit margin11.09%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts

Partner Offers

Search for Jobs